GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Of 10 analysts covering GRAIL, five rate it Hold, four Buy and one Sell. The average 12-month price target is $67.78, below the reported share price of $68.94.
• GRAIL beat quarterly estimates: The company reported a quarterly loss of $2.56 per share versus the $2.66 consensus loss, while revenue of $44.69 million exceeded estimates of $42.39 million. Analysts expect a full-year loss of approximately $10.41 per share.
• Ownership activity was mixed: An insider sold 1,491 shares, while several institutional investors increased their holdings, including JPMorgan, which raised its position by 115.7%.

Shares of GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) have received a consensus rating of "Hold" from the ten analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $67.7778.

A number of research analysts have issued reports on the company. TD Cowen reiterated a "buy" rating on shares of GRAIL in a research report on Wednesday, July 15th. Robert W. Baird set a $70.00 target price on shares of GRAIL in a report on Wednesday, May 6th. Mizuho raised their price target on shares of GRAIL from $58.00 to $65.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of GRAIL in a report on Friday, July 17th. Finally, Piper Sandler upped their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 6th.

Insider Buying and Selling at GRAIL

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider owned 163,738 shares of the company's stock, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.83% of the company's stock.

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently modified their holdings of GRAL. Royal Bank of Canada increased its holdings in GRAIL by 17.7% in the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company's stock worth $2,250,000 after purchasing an additional 13,264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock valued at $76,000 after purchasing an additional 623 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of GRAIL by 390.3% during the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after purchasing an additional 1,401 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of GRAIL by 37.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock valued at $2,362,000 after purchasing an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of GRAIL by 115.7% during the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company's stock valued at $4,090,000 after purchasing an additional 42,675 shares in the last quarter.

GRAIL Stock Performance

Shares of GRAL stock opened at $68.94 on Thursday. The stock's fifty day moving average price is $67.39 and its two-hundred day moving average price is $65.59. The company has a market cap of $3.08 billion, a PE ratio of -7.07 and a beta of 3.24. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. On average, equities analysts predict that GRAIL will post -10.41 EPS for the current fiscal year.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source